Biotech News

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

Biogen (BIIB)Biogen2026-10-29 10:59 ESTClinical readout

Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts. Presentations will include expanded data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of lecanemab (brand name: LEQEMBI ® ).

Related news

BIIBBiogen2026-10-19 11:30 EST

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

BIIBBiogen2026-09-03 23:30 EST

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

NBIXNeurocrine Biosciences2026-10-20 12:30 EST

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

ARWRArrowhead Pharmaceuticals2026-09-29 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

ARWRArrowhead Pharmaceuticals2026-11-02 12:30 EST

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

PHVSPharvaris2026-10-29 10:50 EST

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

ANNXAnnexon, Inc.2026-09-24 12:00 EST

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

View all latest news

Biogen

Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.

Recent company news

BIIBBiogen2026-10-29 10:59 EST

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

BIIBBiogen2026-10-19 11:30 EST

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

BIIBBiogen2026-10-02 15:20 EST

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

BIIBBiogen2026-09-17 20:15 EST

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

BIIBBiogen2026-09-16 06:00 EST

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

Stock data

Close: 243.93 USD
Market cap: 27.88B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States